The American Thyroid Association recently classified all MEN2A-associated codons into increasing risk levels A-C and stated that some patients may delay prophylactic thyroidectomy if certain criteria are met. One criterion is a less aggressive family history of MTC but whether families with the same mutated codon have variable MTC aggressiveness is not well described. We developed several novel measures of MTC aggressiveness and compared families with the same mutated codon to determine if there is significant inter-familial variability. Pedigrees of families with MEN2A were reviewed for codon mutated and proportion of RET mutation carriers with MTC. Individuals with MTC were classified as having local or distant MTC and whether they had pr...
Results of screening and follow-up in a family with the MEN-2A syndrome are described. Fourteen (83%...
Background: Familial Medullary Thyroid Cancer (FMTC) is hereditary in 25% of cases. Patients with an...
Context: Over the last decade, our knowledge of the multiple endocrine neoplasia (MEN) type 2 syndro...
The American Thyroid Association recently classified all MEN2A-associated codons into increasing ris...
Medullary thyroid carcinoma (MTC) represents 3-5% of thyroid cancers. 75% is sporadic and 25% is the...
MEN-2A is characterized by medullary thyroid carcinoma (MTC) with pheochromocytoma and sometimes par...
Introduction Most familial MTC is caused by a germline mutation of the RET proto-oncogene. Rare fa...
Twenty-five percent of medullary thyroid cancers (MTC) are familial and inherited as an autosomal do...
Medullary thyroid carcinoma (MTC) represents 3-5% of thyroid cancers. 75% is sporadic and 25% is the...
Hereditary medullary thyroid carcinoma (MTC) appears in three forms: 1) in association with pheochro...
AbstractBackgroundMultiple endocrine neoplasia type 2A (MEN2A) is a rare cancer associated-syndrome,...
Background Occurrence in a familial setting is well established for medullary thyroid carcinoma (MTC...
Context To date, penetrance figures for medullary thyroid cancer (MTC) for variants in rearranged d...
Differentiated thyroid carcinoma (DTC) represents more than 90% of all thyroid cancer histological t...
BACKGROUND: Pathogenic germline mutations affecting the RET proto-oncogene underlie the development ...
Results of screening and follow-up in a family with the MEN-2A syndrome are described. Fourteen (83%...
Background: Familial Medullary Thyroid Cancer (FMTC) is hereditary in 25% of cases. Patients with an...
Context: Over the last decade, our knowledge of the multiple endocrine neoplasia (MEN) type 2 syndro...
The American Thyroid Association recently classified all MEN2A-associated codons into increasing ris...
Medullary thyroid carcinoma (MTC) represents 3-5% of thyroid cancers. 75% is sporadic and 25% is the...
MEN-2A is characterized by medullary thyroid carcinoma (MTC) with pheochromocytoma and sometimes par...
Introduction Most familial MTC is caused by a germline mutation of the RET proto-oncogene. Rare fa...
Twenty-five percent of medullary thyroid cancers (MTC) are familial and inherited as an autosomal do...
Medullary thyroid carcinoma (MTC) represents 3-5% of thyroid cancers. 75% is sporadic and 25% is the...
Hereditary medullary thyroid carcinoma (MTC) appears in three forms: 1) in association with pheochro...
AbstractBackgroundMultiple endocrine neoplasia type 2A (MEN2A) is a rare cancer associated-syndrome,...
Background Occurrence in a familial setting is well established for medullary thyroid carcinoma (MTC...
Context To date, penetrance figures for medullary thyroid cancer (MTC) for variants in rearranged d...
Differentiated thyroid carcinoma (DTC) represents more than 90% of all thyroid cancer histological t...
BACKGROUND: Pathogenic germline mutations affecting the RET proto-oncogene underlie the development ...
Results of screening and follow-up in a family with the MEN-2A syndrome are described. Fourteen (83%...
Background: Familial Medullary Thyroid Cancer (FMTC) is hereditary in 25% of cases. Patients with an...
Context: Over the last decade, our knowledge of the multiple endocrine neoplasia (MEN) type 2 syndro...